Novel Treatments & Drugs

SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma

Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]

Read More »

Galinpepimut-S Cancer Vaccine in Combination with Opdivo

Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy[…]

Read More »

Vudalimab for the Treatment of Mesothelioma

The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]

Read More »

Proton Beam Radiation Therapy Use Increases for Mesothelioma and Lung Cancer

Proton beam radiation therapy is growing in popularity for treating mesothelioma and lung cancer. A study in JAMA Oncology looked at the use of this radiation for treating different types of cancer. There were almost 6 million patients in the study and data shows that proton radiation use tripled from[…]

Read More »

Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma

A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]

Read More »

High HITHOC Dosage for Pleural Mesothelioma Improves Survival

High doses of hyperthermic intrathoracic chemotherapy (HITHOC) help pleural mesothelioma patients. A recent study found that when HITHOC is administered at a high dose, survival rates improve and periods of being disease free increase. HITHOC is the use of chemotherapy during surgery and is an experimental treatment for different types[…]

Read More »

Platelet Count Can Potentially Influence Mesothelioma Survival

Mesothelioma is a hard-to-treat cancer. Usually chemotherapy, surgery, radiotherapy, and immunotherapy are used, but they do not do enough to save people’s lives. Scientists may have figured out why this is the case and could potentially have found the main causes that affect survival. These include stage of the tumor,[…]

Read More »

A Cancer Vaccine Could Potentially Help Mesothelioma Patients

Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future.  The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually[…]

Read More »

Researchers are Targeting Fibrosis to Improve Mesothelioma Care

Researchers have found that targeting lung fibrosis can help people with mesothelioma. People with mesothelioma usually suffer from fibrosis, which is the stiffening of tissue surrounding tumors. Certain drugs to treat mesothelioma are not very effective because the fibrosis prevents the drugs from penetrating the tumor. It also prevents the[…]

Read More »

OT-101 Useful for COVID-19 and Cancers Like Mesothelioma

Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]

Read More »